Armata Pharmaceuticals Files 8-K on Officer/Director Changes
Ticker: ARMP · Form: 8-K · Filed: Oct 3, 2024 · CIK: 921114
| Field | Detail |
|---|---|
| Company | Armata Pharmaceuticals, INC. (ARMP) |
| Form Type | 8-K |
| Filed Date | Oct 3, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
TL;DR
Armata Pharma 8-K: Leadership changes and financial updates filed.
AI Summary
Armata Pharmaceuticals, Inc. filed an 8-K on October 3, 2024, reporting events as of September 30, 2024. The filing indicates changes related to the departure of directors or officers, election of directors, appointment of officers, and compensatory arrangements. It also includes financial statements and exhibits.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors or officers can indicate internal shifts or strategic realignments that may carry inherent business risks.
Key Players & Entities
- Armata Pharmaceuticals, Inc. (company) — Registrant
- September 30, 2024 (date) — Date of earliest event reported
- October 3, 2024 (date) — Filing date
FAQ
What specific officer or director positions were affected by the changes reported in this 8-K?
The filing indicates "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" but does not specify the names or exact roles within this summary.
Are the compensatory arrangements mentioned related to new hires or existing personnel?
The filing notes "Compensatory Arrangements of Certain Officers" but does not provide details on whether these are for new or existing officers in this summary.
What types of financial statements and exhibits are included with this 8-K filing?
The filing states "Financial Statements and Exhibits" are included, but the specific nature of these documents is not detailed in the provided text.
Does the 8-K mention any specific reasons for the departure of directors or officers?
The filing lists "Departure of Directors or Certain Officers" as an item, but the reasons for these departures are not specified in the provided summary.
What is the significance of the "Date as of Change" being September 30, 2024?
This date indicates the effective date for the events reported in the 8-K filing, such as changes in officers or directors.
Filing Stats: 578 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-10-03 16:15:37
Filing Documents
- tm2425499d1_8k.htm (8-K) — 25KB
- tm2425499d1_ex10-1.htm (EX-10.1) — 53KB
- 0001104659-24-105853.txt ( ) — 263KB
- armp-20240930.xsd (EX-101.SCH) — 3KB
- armp-20240930_lab.xml (EX-101.LAB) — 33KB
- armp-20240930_pre.xml (EX-101.PRE) — 22KB
- tm2425499d1_8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On September 26, 2024, Armata Pharmaceuticals, Inc. (the " Company ") disclosed that it had reached an agreement with Richard Rychlik, the Company's Vice President, Corporate Controller, pursuant to which Mr. Rychlik's employment would conclude effective as of September 30, 2024. In connection with Mr. Rychlik's separation, on September 30, 2024, the Company entered into a Confidential Separation and Release Agreement with Mr. Rychlik (the " Separation Agreement ") pursuant to which, in consideration for Mr. Rychlik's general release of claims in favor of the Company and its affiliates, Mr. Rychlik will be entitled to the continued payment of his base salary through December 31, 2024 and subsidized COBRA premiums for the same period. Mr. Rychlik's receipt of the foregoing payments and benefits is subject to his compliance with the Separation Agreement. The foregoing summary of the Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Separation Agreement, a copy of which is attached as Exhibit 10.1 to this report and is incorporated by reference herein. - 2 -
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 10.1 Confidential Separation and Release Agreement by and between Armata Pharmaceuticals, Inc. and Richard Rychlik dated as of September 30, 2024. 104 Cover Page Interactive Data File (embedded within XBRL document) - 3 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 3, 2024 Armata Pharmaceuticals, Inc. By: /s/ David D. House Name: David D. House Title: Senior Vice President, Finance and Principal Financial Officer - 4 -